Genmab — Januar 2025
-
small new trial - Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders PTLD - https://clinicaltrials.gov/study/NCT06672705
-
Vitus - den analyse sad sgu ikke lige skabet
-
-
Danske helårsregnskaber 2024: Fokus på guidance, moderat vækst og fremtidens USA https://proinvestor.com/boards/123960
-
At the recent IRT conference, Genmab USA’s IRT manager, Madeline Tremont, discussed how the company implemented IRT systems for their first-in-human (FIH) clinical trials. https://informaconnect.com/streamlining-first-in-human-trials-with-irt-systems/ What is Interactive Response Technology (IRT)? https://www.suvoda.com/insights/blog/what-is-interactive-response-technology-irt
-
Top 25 Biotech Companies Heading Into 2025 https://www.genengnews.com/industry-news/top-25-biotech-companies-heading-into-2025/ - -
will Genmab manage to get back into that list again...? -
Life Science vinderaktier 2024 – sådan gik det https://proinvestor.com/investornyt/1262130/life-science-vinderaktier-2024-sadan-gik-det
-
-
J&J's Rybrevant, Lazcluze combo significantly improves survival over Tagrisso in lung cancer https://firstwordpharma.com/story/5925447
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind